Workflow
Praxis(PRAX)
icon
Search documents
Praxis Precision Medicines (PRAX) Investor Presentation - Slideshow
2022-08-11 17:55
PRAXIS 0 CORPORATE OVERVIEW August 2022 Forward-looking statements 2 This presentation may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to our business, operations, and financial conditions, including but not limited to express or implied statements regarding the current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, our development plans, our preclinical and clinical results ...
Praxis(PRAX) - 2022 Q2 - Quarterly Report
2022-08-08 20:07
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39620 PRAXIS PRECISION MEDICINES, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 47-5195942 (State or other ...
Praxis(PRAX) - 2022 Q1 - Earnings Call Presentation
2022-05-13 18:46
PRAXIS ● CORPORATE OVERVIEW May 2022 Forward-looking statements 2 This presentation may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to our business, operations, and financial conditions, including but not limited to express or implied statements regarding the current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, our development plans, our preclinical and clinical results an ...
Praxis(PRAX) - 2022 Q1 - Earnings Call Transcript
2022-05-10 01:11
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Q1 2022 Earnings Conference Call May 9, 2022 4:30 PM ET Company Participants Marcio Souza – President and Chief executive Officer Bernard Ravina – Chief Medical Officer Alex Kane – Vice President Investor Relations and Corporate Communications Conference Call Participants Lauren Riaz – Piper Sandler Laura Chico – Wedbush Securities Yasmeen Rahimi – Piper Sandler Ritu Baral – Cowen & Company Myles Minter – William Blair Douglas Tsao – H.C. Wainwright Operat ...
Praxis(PRAX) - 2022 Q1 - Quarterly Report
2022-05-09 20:08
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39620 PRAXIS PRECISION MEDICINES, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 47-5195942 (State or other ...
Praxis(PRAX) - 2021 Q4 - Earnings Call Transcript
2022-02-28 18:21
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Q4 2021 Earnings Conference Call February 28, 2022 8:30 AM ET Company Participants Marcio Souza – President and Chief Executive Officer Bernard Ravina – Chief Medical Officer Alex Kane – Vice President of Investor Relations and Corporate Communications Conference Call Participants Yasmeen Rahimi – Piper Sandler Laura Chico – Wedbush Securities Ritu Baral – Cowen & Company Tazeen Ahmad – Bank of America Merrill Lynch Myles Minter – William Blair Douglas Tsao – H ...
Praxis(PRAX) - 2022 Q4 - Earnings Call Presentation
2022-02-28 17:24
CORPORATE OVERVIEW FEBRUARY 2022 CONFIDENTIAL PAGE 1 PAGE 1 Forward-looking statements This presentation may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to our business, operations, and financial conditions, including but not limited to express or implied statements regarding the current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, our development plans, our preclinical an ...
Praxis(PRAX) - 2021 Q4 - Annual Report
2022-02-28 11:17
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from________ to_________ Commission File Number: 001-39620 PRAXIS PRECISION MEDICINES, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 47-5195942 (St ...
Praxis(PRAX) - 2021 Q3 - Earnings Call Transcript
2021-11-07 08:46
Start Time: 08:30 January 1, 0000 9:22 AM ET Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Q3 2021 Earnings Conference Call November 03, 2021, 08:30 AM ET Company Participants Marcio Souza - President and CEO Bernard Ravina - Chief Medical Officer Tim Kelly - CFO Alex Kane - VP of IR and Corporate Communications Conference Call Participants Ritu Baral - Cowen & Company Yasmeen Rahimi - Piper Sandler Laura Chico - Wedbush Securities Myles Minter - William Blair Tazeen Ahmad - Bank of America Merrill Lynch O ...
Praxis(PRAX) - 2021 Q3 - Earnings Call Presentation
2021-11-03 19:31
PRAXIS 3 Q 2 0 2 1 CORPORATE UPDATE N o v e m b e r 2 0 2 1 PAGE 1 Forward-looking statements This presentation may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to our business, operations, and financial conditions, including but not limited to express or implied statements regarding the current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, our development plans, our preclin ...